摘要
目的观察替罗非班对后循环进展性卒中的疗效及安全性。方法 24例符合诊断标准的患者分成替非罗班治疗组和常规治疗组,替非罗班治疗组在常规治疗组治疗的基础上加用替罗非班,比较两组治疗后的NIHSS评分。结果替罗非班治疗后7 d及30 d NIHSS评分显著低于常规治疗组(P<0.05),但重度残疾和病死例数比较无统计学差异。结论替罗非班对后循环进展性卒中治疗是安全的,可改善神经功能损害程度,但未降低重度致残和病死例数。
Objective To explore the effectiveness and safety of the Tirofiban for the progressive stroke of posterior circulation. Methods The 24 cases meeting the diagnostic criterion were included in this study and devided into the treatment and control group. Tirofiban was added in treatment group on the base of drug use in control group. The score of NIHSS after treatment between two group were compared. Results The score of the treatment group was decreased significantly both 7 days and 30 days after added Tirofiban. But the number of severe disable case and death case between both groups were the same. No fatal bleeding case occurred in treatment group. Conclusion Tirofiban is safe for the progressive stroke of posterior circulaiton and can ameliorate the neurologic deficit, but can＇t decrease the number of severe disable and death cases.
出处
《实用医药杂志》
2014年第3期197-198,共2页
Practical Journal of Medicine & Pharmacy
关键词
进展性卒中
后循环
替罗非班
Progressive stroke
Posterior circulation
Tirofiban
